{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:51:55Z","timestamp":1788555115544,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,30]]},"DOI":"10.1093\/cid\/ciy827","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T07:44:15Z","timestamp":1538639055000},"page":"1981-1989","source":"Crossref","is-referenced-by-count":162,"title":["Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial"],"prefix":"10.1093","volume":"68","author":[{"given":"Bart Jan","family":"Kullberg","sequence":"first","affiliation":[{"name":"Radboud Center for Infectious Diseases, and Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Viscoli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze della Salute, University of Genova"},{"name":"Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Medical College of Georgia\/Augusta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[{"name":"University of Texas, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman","family":"Rotstein","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D","family":"Sobel","sequence":"additional","affiliation":[{"name":"Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires de Strasbourg and Universit\u00e9 de Strasbourg, Inserm, UMR-S1113\/IRFAC, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[{"name":"Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutep","family":"Jaruratanasirikul","sequence":"additional","affiliation":[{"name":"Songklanagarind Hospital, Hat Yai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[{"name":"Srinagarind Hospital, Khon Kaen University, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Wijngaerden","sequence":"additional","affiliation":[{"name":"Ku Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"De Waele","sequence":"additional","affiliation":[{"name":"Ghent University Hospital, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lademacher","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kovanda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Croos-Dabrera","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fredericks","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"2019053001005207000_CIT0001","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2019053001005207000_CIT0002","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019053001005207000_CIT0003","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","article-title":"Impact of therapeutic strategies on the prognosis of candidemia in the ICU","volume":"42","author":"Puig-Asensio","year":"2014","journal-title":"Crit Care Med"},{"key":"2019053001005207000_CIT0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019053001005207000_CIT0005","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from Phase 1 and Phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019053001005207000_CIT0006","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2019053001005207000_CIT0007","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a Phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2019053001005207000_CIT0008","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019053001005207000_CIT0009","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019053001005207000_CIT0010","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019053001005207000_CIT0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkn431","article-title":"Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei","volume":"63","author":"Majithiya","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2019053001005207000_CIT0012","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"2019053001005207000_CIT0013","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"Rodriquez-Tudela","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2019053001005207000_CIT0014","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard","author":"Clinical and Laboratory Standards Institute","edition":"2nd ed"},{"key":"2019053001005207000_CIT0015","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2019053001005207000_CIT0016","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019053001005207000_CIT0017","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2019053001005207000_CIT0018","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"2019053001005207000_CIT0019","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"2019053001005207000_CIT0020","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"2019053001005207000_CIT0021","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019053001005207000_CIT0022","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/12\/1981\/28739342\/ciy827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T01:01:03Z","timestamp":1559178063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/12\/1981\/5115695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,10,5]]},"published-print":{"date-parts":[[2019,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy827","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,15]]},"published":{"date-parts":[[2018,10,5]]}}}